Complete Removal of the Trabecular Meshwork in Glaucoma
A device for the complete removal of the Trabecular Meshwork in Glaucoma patients—MIGS that is safer, and more effective.
Glaucoma is the leading cause of preventable irreversible blindness globally.
Reduction of intraocular pressure (IOP) is the only way currently available to prevent glaucoma-related blindness.
Reduction of IOP can be achieved mainly by increasing outflow (improving ocular drainage). The main area of resistance to flow is thought to be in the Trabecular Meshwork (TM).
Over the past decade, incising the TM has been shown to be effective, though leaving the incised tissue in the eye can induce scarring and potentially affect efficacy as well as safety. We believe tissue removal would be advantageous.
Inventors
Contact info
Avital Pritz, Director of Medical Devices and Digital Health
For further information please contact:
avital@mor-research.comRemoval of the TM in its entirety using a minimally invasive approach by using a unique micro-knife threaded on a suture.
The global minimally invasive glaucoma surgery (MIGS) devices market size was estimated at USD 539.6 million in 2023 and is anticipated to grow at a CAGR of 5.36% from 2024 to 2030. The growing awareness regarding minimally invasive surgery, technological advancements, rising geriatric populations, and growing healthcare infrastructures are the major factors contributing to market growth.
Preliminary successful POC achieved in cadaver eyes.
Currently conducting additional experiments on a complete eye model, with results expected during Q1 2024.